Clinical trials: Human Cancers
Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma.
- Conditions
- Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Follicular Lymphoma
- Trial name
- NCT05512390
- Testing
- ABBV-319
- Where
- 20 sites in United States, Australia and 4 more
- Volunteers
- 39 people
- Sponsor
- AbbVie
Cutaneous Melanoma, Synovial Sarcoma
ACTengine® IMA203 Combined With mRNA-4203
This purpose of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA203 in combination with different doses of mRNA-4203.
- Trial name
- NCT06946225
- Testing
- IMA203, mRNA-4203
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Immatics US, Inc.
HER2-positive Breast Cancer, HER2-positive Gastric Cancer
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
A Study of XMT-2056 in advanced/recurrent solid tumors that express HER2.
- Conditions
- HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Non-Small Cell Lung Cancer, HER2-positive Colorectal Cancer
- Trial name
- NCT05514717
- Testing
- XMT-2056
- Where
- 14 sites in United States
- Volunteers
- 57 people
- Sponsor
- Day One Biopharmaceuticals, Inc.
Chemotherapy-induced Thrombocytopenia
A Study of the Recombinant Human Interleukin-11 (I) (Baijieyi) for Prevention and Treatment of Chemotherapy-induced Thrombocytopenia in Patients With Malignant Tumor
The aim of this retrospective study is to review and describe the safety and the efficacy of recombinant human interleukin-11 (I) i (Baijieyi), using information already recorded in 20 medical records, The time periods include…
- Trial name
- NCT03049774
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Angde Biotech Pharmaceutical Co., Ltd.
Breast Cancer, Breast Cancer Metastatic
A First-in-human, Clinical Trial Assessing the Safety of ES2B-C001-S01 With or Without [Adjuvant] in Patients With HER2-expressing Metastatic Breast Cancer.
The trial is a first-in-human, phase I, open-label, dose-escalating trial to assess the safety and tolerability of ES2B-C001 combined with or without [adjuvant], in patients with human epidermal growth factor receptor 2 (HER2)…
- Trial name
- NCT06746688
- Testing
- ES2B-C001, ISA 51 VD
- Where
- 3 sites in Austria
- Volunteers
- 40 people
- Sponsor
- ExpreS2ion Biotechnologies
NSCLC
Safety and Efficacy of NK510 to Treat NSCLC
This study assesses the safety and efficacy of NK510 combined with PD-(L)1 inhibitors for relapsed/refractory advanced NSCLC, with two administration routes: intravenous infusion and intrapleural perfusion for malignant pleural…
- Trial name
- NCT06097962
- Testing
- NK510, Tislelizumab，atezolizumab or sugemalimab, systemic therapy as selected by the investigator
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Base Therapeutics (Shanghai) Co., Ltd.
Advanced Solid Tumor
AMT-253 in Patients With Selected Advanced Solid Tumours
This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-253, in…
- Trial name
- NCT05906862
- Testing
- AMT-253
- Where
- 7 sites in Australia
- Volunteers
- 54 people
- Sponsor
- Multitude Therapeutics (Australia) Pty Ltd
Glioblastoma, High-grade Glioma
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
This is a draft, ClinicalTrials.gov-style example record for a first-in-human Phase 1 study evaluating locoregional administration of dual-targeting chimeric antigen receptor natural killer (CAR-NK) cells in adults with recurrent…
- Conditions
- Glioblastoma, High-grade Glioma, Malignant Glioma, Recurrent Glioblastoma
- Trial name
- DUAL-CAR-NK-GB (NCT07480941)
- Testing
- Dual-target CAR-NK cells, Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
Cholangiocarcinoma, Chondrosarcoma
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with isocitrate dehydrogenase 1 (IDH1) arginine 132 (R132)-mutant advanced solid tumors…
- Conditions
- Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor
- Trial name
- NCT04521686
- Testing
- LY3410738, Gemcitabine, Cisplatin
- Where
- 33 sites in United States, Australia and 7 more
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer
A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors
The purpose of the trial is to evaluate the safety, determine the recommended Phase 2 dose (RP2D), and assess preliminary clinical activity of GEN1044 in patients with solid tumors.
- Conditions
- Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer, Esophageal Cancer, Triple Negative Breast Cancer (TNBC)
- Trial name
- NCT04424641
- Testing
- GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.
- Where
- 6 sites in United States, Denmark and 2 more
- Volunteers
- 48 people
- Sponsor
- Genmab
Hepatocellular Carcinoma, Hepatocellular Cancer
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
The primary objective is to assess overall sensitivity and specificity of Oncoguard™ Liver for hepatocellular cancer (HCC) detection in a surveillance population.
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis
- Trial name
- NCT05064553
- Testing
- Study CT/MRI Imaging, Standard of Care CT/MRI Imaging, Oncoguard™ Liver Test
- Where
- 76 sites in United States
- Volunteers
- 2,990 people
- Sponsor
- Exact Sciences Corporation
WHIM Syndrome
A Retrospective and Prospective Natural History Study of Patients With WHIM Syndrome
This natural history study is a prospective and retrospective, observational study of WHIM patients. WHIM syndrome is a rare, genetic, primary immunodeficiency disorder (a disorder in which the body's immune system does not…
- Trial name
- NCT03087370
- Testing
- No intervention
- Sponsor
- X4 Pharmaceuticals
Infections, Papillomavirus
Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Indeed, certain oncogenic types of HPV can infect the cervix (part of the uterus or womb).
- Trial name
- NCT00196937
- Testing
- Cervarix
- Where
- 6 sites in Germany, Poland
- Volunteers
- 667 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Breast Cancer
Estimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low Status
This is a worldwide, multicenter, non-interventional, retrospective study of patient medical records from metastatic breast cancer (mBC) patients previously identified as human epidermal growth factor receptor 2 negative…
- Trial name
- NCT04807595
- Testing
- None (Observational study)
- Where
- 13 sites in United States, Australia and 8 more
- Volunteers
- 798 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
Study of TRM-1(TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to evaluate the efficacy and safety of TRM-1 in subjects with relapsed or refractory non-small cell lung cancer.
- Trial name
- NCT00092924
- Testing
- TRAIL-R1 mAb (TRM-1;HGS-ETR1)
- Where
- 5 sites in United States
- Sponsor
- Human Genome Sciences Inc.
Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies
The clinical study will assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory solid tumor malignancies or lymphoma.
- Trial name
- NCT03739931
- Testing
- mRNA-2752, Durvalumab
- Where
- 24 sites in United States, Australia and 1 more
- Volunteers
- 134 people
- Sponsor
- ModernaTX, Inc.
Neoplasms
First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL)
Arginine methylation mediated by protein arginine methyl-transferases (PRMTs) is an important post-translational modification of proteins involved in a diverse range of cellular processes.
- Trial name
- NCT03666988
- Testing
- GSK3368715
- Where
- 9 sites in United States, Australia and 2 more
- Volunteers
- 31 people
- Sponsor
- GlaxoSmithKline
Neoplasms, Breast
Treatment Options in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer Patients
This study will describe the treatment paradigm used over recent years in the clinical management of Human Epidermal Growth Factor Receptor 2 (HER2)+ metastatic breast cancer in Hungary.
- Trial name
- NCT01782651
- Testing
- Lapatinib plus capecitabine
- Where
- Hungary
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Human Papillomavirus Infection
APTIMA HPV 16 18/45 Genotype Assay on the TIGRIS DTS System in Women With ASC-US or Negative Pap Test Results
In both the ASC-US Study and Adjunct Study populations, the objectives are to: evaluate the performance characteristics of the AHPV-GT Assay for detecting cervical disease in women with APTIMA HPV Assay positive results and…
- Trial name
- AHPV-GT (NCT01384370)
- Where
- 3 sites in United States
- Volunteers
- 1,260 people, healthy volunteers welcome
- Sponsor
- Gen-Probe, Incorporated
Advanced Malignant Solid Tumor
First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors
This study is investigating a new experimental therapy, MP0317, a DARPin® drug candidate targeting fibroblast activation protein (FAP) and CD40.
- Trial name
- NCT05098405
- Testing
- MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q3w regimen), MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q1w regimen)
- Where
- 4 sites in France, Netherlands
- Volunteers
- 46 people
- Sponsor
- Molecular Partners AG
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.